Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...
Lana Hart, 29, has given a searingly honest account about why she turned to weight loss injection Mounjaro amid a national ...
Novo Nordisk's CagriSema trial raised concerns as patients reported weight loss but significant side effects. Investors ...
Telehealth company Hims & Hers' first Super Bowl ad is provocative and effective in building awareness of its weight loss ...
Actress and comedian Amy Schumer said she took Ozempic three years ago and quickly lost 30 lbs. However, she quit the ...
Expanded Ozempic approval in the U.S. could transform how doctors treat patients with chronic kidney disease, which involves ...
NPA chairman Nick Kaye told the PA news agency that while obesity is "one of the biggest challenges facing" the UK, they are ...
The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go ...
Novo Nordisk NVO is scheduled to report fourth-quarter 2024 results on Feb. 5, 2025, before the opening bell. The Zacks ...
marketed as Ozempic pre-filled pen and Rybelsus oral tablet for T2D and as Wegovy injection for weight management. Wegovy is a significant contributor to Novo Nordisk's revenues. Despite supply ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback